Morphotek clinical trials

Acquired by Eisai Co., Ltd.

The registry lists 21 studies whose lead sponsor is Morphotek. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Mar 29, 2024.

Studies

Recruiting first, then most recently updated. Showing 21 of 21. All Eisai Co., Ltd. studies →

• Dose Escalation Study MORAb-066 Targeting Tissue Factor (TF)-Expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLCCompletedNCT01761240Phase 1

  Sponsor listed in the registry: Morphotek · Morphotek — acquired company within the Eisai Co., Ltd. group

• Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First RelapseTerminatedNCT00849667Phase 3

  Sponsor listed in the registry: Morphotek · Morphotek — acquired company within the Eisai Co., Ltd. group

• An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural MesotheliomaCompletedNCT00738582Phase 2

  Sponsor listed in the registry: Morphotek · Morphotek — acquired company within the Eisai Co., Ltd. group

• Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)TerminatedNCT01507545Phase 2

  Sponsor listed in the registry: Morphotek · Morphotek — acquired company within the Eisai Co., Ltd. group

• An Open Label Extension Study of the Efficacy of MORAb-003TerminatedNCT01018563Phase 2

  Sponsor listed in the registry: Morphotek · Morphotek — acquired company within the Eisai Co., Ltd. group

• A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the LungCompletedNCT01218516Phase 2

  Sponsor listed in the registry: Morphotek · Morphotek — acquired company within the Eisai Co., Ltd. group

• Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM)TerminatedNCT02357147Phase 2

  Sponsor listed in the registry: Morphotek · Morphotek — acquired company within the Eisai Co., Ltd. group

• Sarcoma Study of MORAb-004 Utilization: Research and Clinical EvaluationCompletedNCT01574716Phase 2

  Sponsor listed in the registry: Morphotek · Morphotek — acquired company within the Eisai Co., Ltd. group

• An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian CancerTerminatedNCT00738699Phase 2

  Sponsor listed in the registry: Morphotek · Morphotek — acquired company within the Eisai Co., Ltd. group

• A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing CancersCompletedNCT01521325Phase 1

  Sponsor listed in the registry: Morphotek · Morphotek — acquired company within the Eisai Co., Ltd. group

• MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or LymphomaCompletedNCT01748721Phase 1

  Sponsor listed in the registry: Morphotek · Morphotek — acquired company within the Eisai Co., Ltd. group

• Safety and Tolerability of MORAb-022 in Healthy and Rheumatoid Arthritis SubjectsCompletedNCT01357759Phase 1

  Sponsor listed in the registry: Morphotek · Morphotek — acquired company within the Eisai Co., Ltd. group

• An Efficacy Study of MORAb-009 in Subjects With Pancreatic CancerCompletedNCT00570713Phase 2

  Sponsor listed in the registry: Morphotek · Morphotek — acquired company within the Eisai Co., Ltd. group

• Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based ChemotherapyCompletedNCT00318370Phase 2

  Sponsor listed in the registry: Morphotek · Morphotek — acquired company within the Eisai Co., Ltd. group

• Safety Study of Farletuzumab, Carboplatin and Pegylated Liposomal Doxorubicin (PLD) to Treat Platinum-sensitive Ovarian CancerCompletedNCT01004380Phase 1

  Sponsor listed in the registry: Morphotek · Morphotek — acquired company within the Eisai Co., Ltd. group

• A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung CancerCompletedNCT00325494Phase 1

  Sponsor listed in the registry: Morphotek · Morphotek — acquired company within the Eisai Co., Ltd. group

• Safety Study of Human IgM (MORAb-028) to Treat Metastatic MelanomaTerminatedNCT01123304Phase 1

  Sponsor listed in the registry: Morphotek · Morphotek — acquired company within the Eisai Co., Ltd. group

• A Safety and MORAb-028 Dose Determination Study in Subjects With Metastatic MelanomaTerminatedNCT01212276Phase 1

  Sponsor listed in the registry: Morphotek · Morphotek — acquired company within the Eisai Co., Ltd. group

• A Study of of MORAb-004 in Subjects With Solid TumorsCompletedNCT00847054Phase 1

  Sponsor listed in the registry: Morphotek · Morphotek — acquired company within the Eisai Co., Ltd. group

• Safety, Tolerability and Pharmacokinetics of MORAb-003 in Subjects With Advanced Ovarian CancerCompletedNCT00428766Phase 1

  Sponsor listed in the registry: Morphotek · Morphotek — acquired company within the Eisai Co., Ltd. group

• Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary AdenomasWithdrawnNCT01203618Phase 2

  Sponsor listed in the registry: Morphotek · Morphotek — acquired company within the Eisai Co., Ltd. group